Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Comprehensive clinical development programs being initiated for each investigational candidate
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
Based on a post hoc analysis, fewer required respiratory interventions
Subscribe To Our Newsletter & Stay Updated
